menu search

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
Data reinforce brilaroxazine’s differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion profiles of brilaroxazine were similar across mice, canines, and humans CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company […] The post Reviva Pharmaceuticals Announces Presentatio... Read More
Posted: May 22 2023, 10:30
Author Name: forextv
Views: 081569

Search within

Pages Search Results: